Literature DB >> 11221840

Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells.

Y Guilloux1, X F Bai, X Liu, P Zheng, Y Liu.   

Abstract

MHC class I-restricted tumor antigen can be presented to CD8+ T cells by two distinct mechanisms. Direct presentation involves degradation of cytosolic proteins by the proteosome into peptides, transport of the peptides across the endoplasmic reticulum membrane, and expression of the MHC-peptide complex on the tumor cell surface. Cross-presentation, on the other hand, involves uptake and intracellular processing of the tumor antigen by host antigen-presenting cells. Whereas it is clear that cross-presentation is necessary and sufficient for the induction of memory CTLs, it has not been tested whether such presentation is sufficient to induce effector CTLs. Here we analyzed the requirements of direct antigen presentation for the induction of effector and memory antitumor CTLs using a MHC class I- mutant incapable of direct antigen presentation and its parent, the MHC class I+ J558 cell line. We report that in comparison with the MHC class I+ tumor cell, the MHC class I- mutant induces equal priming for recall CTL response but poor effector CTLs. Our results demonstrate that optimal induction of effector CTLs, but not memory CTLs, requires direct antigen presentation by the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221840

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

2.  In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Authors:  Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam Levitsky; Eduardo M Sotomayor
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

3.  Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Yun Shi; Xiaotong Zhu; Zhihao Liu; Ming-Song Li; Jianhua Yu; Lai-Chu Wu; Yukai He; Guoqiang Zhang; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

4.  Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.

Authors:  Jennifer Carlring; Munitta Shaif-Muthana; Karen Sisley; Ian G Rennie; Anna K Murray
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

5.  Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response.

Authors:  Silvia Sartoris; Maria G Testi; Elisabetta Stefani; Roberto Chignola; Chiara Guerriero; Andrea Matucci; Tiziana Cestari; Aldo Scarpa; Anna P Riviera; Giovanna Zanoni; Giuseppe Tridente; Giancarlo Andrighetto
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

6.  B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo.

Authors:  X Liu; X F Bai; J Wen; J X Gao; J Liu; P Lu; Y Wang; P Zheng; Y Liu
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

7.  Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.

Authors:  Kang Liu; Juliana Idoyaga; Anna Charalambous; Shin-Ichiro Fujii; Anthony Bonito; Jose Mordoh; Rosa Wainstok; Xue-Feng Bai; Yang Liu; Ralph M Steinman
Journal:  J Exp Med       Date:  2005-12-05       Impact factor: 14.307

8.  Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

Authors:  Ping Yu; Michael T Spiotto; Youjin Lee; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2003-04-14       Impact factor: 14.307

9.  Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Authors:  Jérémie Ménager; Jean-Baptiste Gorin; Catherine Maurel; Lucile Drujont; Sébastien Gouard; Cédric Louvet; Michel Chérel; Alain Faivre-Chauvet; Alfred Morgenstern; Frank Bruchertseifer; François Davodeau; Joëlle Gaschet; Yannick Guilloux
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

10.  Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Authors:  Marta Mazzocco; Matteo Martini; Antonio Rosato; Elisabetta Stefani; Andrea Matucci; Silvia Dalla Santa; Francesco De Sanctis; Stefano Ugel; Sara Sandri; Giovanna Ferrarini; Tiziana Cestari; Sergio Ferrari; Paola Zanovello; Vincenzo Bronte; Silvia Sartoris
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.